Prestige BioPharma invests its expertise and resources in the development of biosimilars and new first-in-class antibody therapeutics.
PBP’s current biosimilar portfolio includes:

HD201 (Herceptin Biosimilar)

HD204 (Avastin Biosimilar)

PBP1502 (Humira Biosimilar)

PBP’s current first in class antibody therapeutics portfolio includes:

PBP1510 Anti-PAUF Antibody for Pancreatic Cancer

PBP1710 Anti-CTHRC1 Antibody for Solid Tumors

The first biosimilar of PBP, HD201 Trastuzumab, has been filed and accepted for review with the EMA, projecting market launch in 2021. Prestige BioPharma´s next products in line include a Bevacizumab biosimilar (HD204) in Phase III, an Adalimumab biosimilar (PBP1502) in Phase I, and an innovative anti-PAUF mAb (PBP1510) for the treatment of pancreatic cancer in Phase I stages. Manufacturing facilities for global commercial supply are located in Osong, South Korea.

DrugCategoryIndication
HD201Biosimilar, Trastuzumab (Herceptin)Breast Cancer, Gastric Cancer
HD204Biosimilar, Bevacizumab (Avastin)Solid Tumors
PBP1502Biosimilar, Adalimumab (Humira)Arthritis
PBP1510First In Class AntibodyPancreatic Cancer
PBP1601Biosimilar, Denosumab Bone Loss, Osteoporosis
PBP1602Biosimilar, Aflibercept Macular Edema, Metastatic Colorectal Cancer, Retinopathy
PBP1603Biosimilar, Eculizumab Atypical Haemolytic Uremic Syndrome, Paraoxysmal Nocturnal Hemoglobinuria
PBP1701Biosimilar, Ipilimumab Metastatic Melanoma, Unresectable Melanoma
PBP1710First In Class AntibodySolid Tumors
PBP1801Biosimilar, Pertuzumab (Perjeta)Breast Cancer

Development Stage

  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • MAA/BLA
  • HD201 TRASTUZUMAB BIOSIMILAR
    INDICATION: BREAST CANCER, GASTRIC CANCER
  • HD204 BEVACIZUMAB BIOSIMILAR
    INDICATION: SOLID TUMORS
  • PBP1502 ADALIMUMAB BIOSIMILAR
    INDICATION: ARTHRITIS
  • PBP1510 First-In-Class ANTIBODY
    INDICATION: PANCREATIC CANCER
  • PBP1601 DENOSUMAB BIOSIMILAR
    INDICATION: BONE LOSS OSTEOPOROSIS
  • PBP1602 AFLIBERCEPT BIOSIMILAR
    INDICATION: MACULAR EDEMA, METASTATIC COLORECTAL CANCER, RETINOPATHY
  • PBP1603 ECULIZUMAB BIOSIMILAR
    INDICATION: ATYPICAL HAEMOLYTIC UREMIC SYNDROME, PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
  • PBP1701 IPILIMUMAB BIOSIMILAR
    INDICATION: METASTATIC MELANOMA, UNRESECTABLE MELANOMA
  • PBP1710 First-In-Class ANTIBODY
    INDICATION: SOLID TUMORS
  • PBP1801 PERTUZUMAB BIOSIMILAR
    INDICATION: BREAST CANCERS
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • MAA/BLA